Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $REGN are available with SpikePanel Pro.
Phase 1/2 trial for non-infectious uveitis terminated after unfavorable benefit-risk review, hitting pipeline
D1 +0.5% · +5d +2.9%
EarningsBull
Regeneron Q2 Beat, Dupixent & Eylea HD Drive Growth
Q2 revenue +17% YoY to $4.291B; Eylea HD US net sales +52%, Libtayo +30%; FDA/EMA accepted cemdisiran filing for gMG
D1 +6.2% · +5d +4.6%
›4 waves of this story
2026-07-30 Q2 results beat on revenue and profit, driven by strong demand for Dupixent and high-dose Eylea.
2026-07-30 Q2 revenue $4.3B beat; Dupixent global sales +38%, Eylea HD US sales +52%
2026-08-05 Citigroup raises PT to $740 post-earnings, reflecting institutional confidence
2026-08-06 Q2 revenue +17% YoY to $4.291B; Eylea HD US net sales +52%, Libtayo +30%; FDA/EMA accepted cemdisiran filing for gMG
RegulationBear
Multiple Law Firms Announce Securities Class Action Lawsuits Against Regeneron
Multiple firms issued reminders with a lead plaintiff deadline of 9/14/2026, alleging statements about the Phase III Fianlimab-Libtayo study.
D1 -0.7% · +5d -0.7%
›18 waves of this story
2026-07-18 At least four independent law firms have announced investigations or lawsuits alleging securities fraud, inviting investors to join.
2026-07-18 Multiple law firms issue reminders, including DJS, Schall, and Faruqi, with deadline on Sept 14, 2026.
2026-07-20 Two additional law firms (DJS Law Group, Schall Law Firm) issued reminders today, same line as prior event, no new facts.
2026-07-20 On July 20, 2026, multiple law firms including Bernstein Liebhard, DJS Law Group, Faruqi & Faruqi, Schall Law Firm, and Levi & Korsinsky issued investor alerts regarding a securities class action lawsuit against Regeneron for alleged securities law violations, with a lead plaintiff deadline set for September 14, 2026.
2026-07-22 Multiple firms confirm class action with Sept 14 deadline, allegations involve Fianlimab-Libtayo trial disclosures.
2026-07-23 Multiple law firms issue class action notices, adding Sept 14 lead plaintiff deadline and Phase 3 trial disclosure allegations
2026-07-24 Multiple law firms issue reminders with Sept 14 deadline, no new facts, just repetition.
2026-07-24 Multiple law firms issued notices today alleging trial misrepresentations, with September 14 deadline highlighted
2026-07-27 BFA, Bronstein, Faruqi among firms flagging Sept 14 lead plaintiff deadline after 9% stock drop triggered fraud suit
2026-07-28 Multiple law firms issue class action reminders, alleging misleading statements on Fianlimab-L Phase III trial; stock fell nearly 10%
2026-08-04 Multiple law firms file class actions over trial disclosures, stock drops nearly 10%
2026-08-04 Multiple firms issued reminders today; lawsuit relates to Fianlimab-L trial failure and stock drop, deadline Sept 14.
2026-08-05 Multiple firms issued reminders with a lead plaintiff deadline of 9/14/2026, alleging statements about the Phase III Fianlimab-Libtayo study.
Analyst
Analysts Raise Regeneron PT & Upgrade
Citi raises PT to $740 (Neutral); Wall Street Zen upgrades to Buy; reflects cautious optimism on Eylea HD & pipeline
D1 +1.0% · +5d +3.8%
CapitalBull
Multiple Institutions Increase Regeneron Holdings
At least 4 law firms file class action alleging securities fraud over trial misrepresentations; lead plaintiff deadline 9/14/2026
D1 +0.5% · +5d +3.0%
›2 waves of this story
2026-07-21 AlTi Global raises 312.7%, Baader Bank 138.7%, Assetmark 9.2%.
2026-08-03 At least 4 law firms file class action alleging securities fraud over trial misrepresentations; lead plaintiff deadline 9/14/2026
ProductBear
Biocon Launches Eylea Biosimilar Yesafili in the US
Biocon announces US launch of Yesafili, competing with Regeneron's Eylea
D1 -0.4% · +5d +6.4%
ProductBear
Biocon Launches Yesafili, a Biosimilar to Regeneron's Eylea 2 mg
Biocon commercially launches Yesafili in the U.S., directly competing with Regeneron's Eylea for ophthalmology conditions
D1 -0.4% · +5d +6.4%
8-K filing
8-K: Item 2.02, Item 9.01
D1 +6.2% · +5d +4.6%
Earnings
Earnings report
2026年第二季度总收入同比增长17%至43亿美元，非GAAP每股收益增长11%至14.29美元。
D1 +6.2% · +5d +4.6%
①
Bull vs bear
by direction · sourced
Bull signals0
None yet
Bear signals0
None yet
Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice
⑩
Discussion
be the first
Be civil · your views are your own
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
Event thread
Key events, in time order
27 items
ProductBull
Regeneron Advances CIDEB Therapy After Early Trial Cuts Liver Fat by Up to 80%
Single dose reduced liver fat by up to 80%, advancing MASH therapy to later-stage studies
D1 -0.4% · since +1.3%
EarningsBull
Regeneron Gets Analyst Target Hikes After Q3 Beat
Multiple analysts raise targets; stock hits 52-week high
D1 +13.3% · +5d -2.5%
›3 waves of this story
2026-10-30 Revenue of $5.1B and adj. EPS of $20.07 beat estimates, driven by Dupixent and Eylea HD growth.
2026-10-31 Dupixent global quarterly sales $6.5B, total revenue +36% YoY; stock hits 52-week high
2026-11-03 Multiple analysts raise targets; stock hits 52-week high
Insider selling
Insider selling $32.3M (3)
D1 +3.6% · +5d -4.3%
Earnings
Earnings report
第三季度总营收同比增长36%至51亿美元，非GAAP每股收益增长70%至20.07美元。
D1 +13.3% · +5d -2.5%
8-K filing
8-K: Item 2.02, Item 9.01
D1 +13.3% · +5d -2.5%
22 earlier events›
CompanyBull
Regeneron Expands BARDA Ebola Drug Supply Deal
Adds ~$270M supply contract, boosting U.S. preparedness stockpile
D1 +0.3% · +5d +19.0%
Capital
Regeneron CSO Sells $3.2M in Stock
Insider Andrew Murphy sold 4,147 shares on Oct 14 under plan, priced $753.76-$781.47
D1 -1.1% · +5d +3.3%
Analyst
UBS upgrades to Buy
D1 +2.3% · +5d +2.9%
ProductBull
Regeneron Reports Positive 84-Week Pasatru Data
Phase 3 OPTIMA shows sustained efficacy in halting rogue bone growth
D1 +2.2% · +5d +2.5%
ProductBull
Regeneron Presents Late-Breaking Libtayo Survival Data at ESMO 2026
Phase 1/2 trial for non-infectious uveitis terminated after unfavorable benefit-risk review, hitting pipeline
D1 +0.5% · +5d +2.9%
EarningsBull
Regeneron Q2 Beat, Dupixent & Eylea HD Drive Growth
Q2 revenue +17% YoY to $4.291B; Eylea HD US net sales +52%, Libtayo +30%; FDA/EMA accepted cemdisiran filing for gMG
D1 +6.2% · +5d +4.6%
›4 waves of this story
2026-07-30 Q2 results beat on revenue and profit, driven by strong demand for Dupixent and high-dose Eylea.
2026-07-30 Q2 revenue $4.3B beat; Dupixent global sales +38%, Eylea HD US sales +52%
2026-08-05 Citigroup raises PT to $740 post-earnings, reflecting institutional confidence
2026-08-06 Q2 revenue +17% YoY to $4.291B; Eylea HD US net sales +52%, Libtayo +30%; FDA/EMA accepted cemdisiran filing for gMG
RegulationBear
Multiple Law Firms Announce Securities Class Action Lawsuits Against Regeneron
Multiple firms issued reminders with a lead plaintiff deadline of 9/14/2026, alleging statements about the Phase III Fianlimab-Libtayo study.
D1 -0.7% · +5d -0.7%
›18 waves of this story
2026-07-18 At least four independent law firms have announced investigations or lawsuits alleging securities fraud, inviting investors to join.
2026-07-18 Multiple law firms issue reminders, including DJS, Schall, and Faruqi, with deadline on Sept 14, 2026.
2026-07-20 Two additional law firms (DJS Law Group, Schall Law Firm) issued reminders today, same line as prior event, no new facts.
2026-07-20 On July 20, 2026, multiple law firms including Bernstein Liebhard, DJS Law Group, Faruqi & Faruqi, Schall Law Firm, and Levi & Korsinsky issued investor alerts regarding a securities class action lawsuit against Regeneron for alleged securities law violations, with a lead plaintiff deadline set for September 14, 2026.
2026-07-22 Multiple firms confirm class action with Sept 14 deadline, allegations involve Fianlimab-Libtayo trial disclosures.
2026-07-23 Multiple law firms issue class action notices, adding Sept 14 lead plaintiff deadline and Phase 3 trial disclosure allegations
2026-07-24 Multiple law firms issue reminders with Sept 14 deadline, no new facts, just repetition.
2026-07-24 Multiple law firms issued notices today alleging trial misrepresentations, with September 14 deadline highlighted
2026-07-27 BFA, Bronstein, Faruqi among firms flagging Sept 14 lead plaintiff deadline after 9% stock drop triggered fraud suit
2026-07-28 Multiple law firms issue class action reminders, alleging misleading statements on Fianlimab-L Phase III trial; stock fell nearly 10%
2026-08-04 Multiple law firms file class actions over trial disclosures, stock drops nearly 10%
2026-08-04 Multiple firms issued reminders today; lawsuit relates to Fianlimab-L trial failure and stock drop, deadline Sept 14.
2026-08-05 Multiple firms issued reminders with a lead plaintiff deadline of 9/14/2026, alleging statements about the Phase III Fianlimab-Libtayo study.
Analyst
Analysts Raise Regeneron PT & Upgrade
Citi raises PT to $740 (Neutral); Wall Street Zen upgrades to Buy; reflects cautious optimism on Eylea HD & pipeline
D1 +1.0% · +5d +3.8%
CapitalBull
Multiple Institutions Increase Regeneron Holdings
At least 4 law firms file class action alleging securities fraud over trial misrepresentations; lead plaintiff deadline 9/14/2026
D1 +0.5% · +5d +3.0%
›2 waves of this story
2026-07-21 AlTi Global raises 312.7%, Baader Bank 138.7%, Assetmark 9.2%.
2026-08-03 At least 4 law firms file class action alleging securities fraud over trial misrepresentations; lead plaintiff deadline 9/14/2026
ProductBear
Biocon Launches Eylea Biosimilar Yesafili in the US
Biocon announces US launch of Yesafili, competing with Regeneron's Eylea
D1 -0.4% · +5d +6.4%
ProductBear
Biocon Launches Yesafili, a Biosimilar to Regeneron's Eylea 2 mg
Biocon commercially launches Yesafili in the U.S., directly competing with Regeneron's Eylea for ophthalmology conditions
D1 -0.4% · +5d +6.4%
8-K filing
8-K: Item 2.02, Item 9.01
D1 +6.2% · +5d +4.6%
Earnings
Earnings report
2026年第二季度总收入同比增长17%至43亿美元，非GAAP每股收益增长11%至14.29美元。
D1 +6.2% · +5d +4.6%
$REGN — what investors on X are saying · SpikePanel
